Kivexa (Abacavir Sulfate, Lamivudine)

Both components are nucleoside analogues that are phosphorylated inside cells to active triphosphates. They compete with natural nucleosides for incorporation by HIV reverse transcriptase, causing premature DNA chain termination and blocking viral replication.

The prescribed dose of Kivexa is determined by the treating clinician based on the patient’s clinical status, weight, and other antiretroviral agents. Dosage adjustments may be required for renal or hepatic impairment, and patients should follow the prescriber’s instructions.

The safety of Kivexa in pregnancy and lactation has not been fully established. Clinicians should evaluate the potential benefits against possible risks, and pregnant or nursing women should discuss treatment options with their healthcare provider.

To request Kivexa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kivexa combines two nucleoside reverse transcriptase inhibitors in a single tablet, offering convenience over separate pills. Compared with other NRTI backbones, it provides a favorable dosing schedule but shares similar efficacy and safety profiles, while requiring HLA‑B*57:01 screening for abacavir hypersensitivity.

Kivexa tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Kivexa is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not split or crushed unless specifically advised.

The most serious risks include a hypersensitivity reaction linked to the HLA‑B*57:01 allele, which can be life‑threatening, as well as severe liver injury, lactic acidosis, and rare dermatologic events such as Stevens‑Johnson syndrome. Immediate medical attention is required if these symptoms occur.

Patients who test positive for the HLA‑B*57:01 allele, those with known hypersensitivity to abacavir or lamivudine, and individuals with severe hepatic impairment should avoid Kivexa. Additionally, it is contraindicated in patients receiving prohibited concomitant medications such as didanosine or stavudine.